Cardiac magnetic resonance imaging (MRI) has become an essential tool in the assessment of myocardial viability. Advances in this technology have significantly improved the ability of clinicians to detect viable heart tissue, which is crucial for guiding treatment decisions in patients with coronary artery disease. The ability to differentiate between scarred, stunned, or hibernating myocardium directly influences whether revascularization—such as percutaneous coronary intervention or coronary artery bypass grafting—will improve left ventricular function and long-term survival. Modern cardiac MRI (CMR) techniques now provide detailed tissue characterization with high spatial resolution, allowing for more precise mapping of myocardial viability than ever before.

What Is Myocardial Viability?

Myocardial viability refers to the functional integrity of heart muscle cells after they have been subjected to ischemia. A viable myocyte is one that is still alive and capable of contracting if adequate blood flow is restored. Conversely, non-viable myocardium, which is predominantly scar tissue, cannot recover function no matter how well revascularization is performed. The concept of viability encompasses several states: stunned myocardium (temporary dysfunction after brief ischemia that recovers spontaneously), hibernating myocardium (chronic dysfunction due to reduced blood flow that recovers after revascularization), and subendocardial or transmural scar (irreversible damage).

Determining viability is critical because revascularization of non-viable tissue exposes patients to procedural risk without benefit, while failure to treat viable but dysfunctional tissue may allow further decline in heart function. The clinical importance is especially pronounced in patients with ischemic cardiomyopathy, where left ventricular ejection fraction is reduced and the ventricle may contain a mix of viable and scarred segments. Advanced imaging techniques now allow clinicians to quantify the transmural extent of scar and the degree of residual viability, enabling personalized therapeutic decisions.

Historical Approaches to Viability Assessment

Before cardiac MRI became widely adopted, clinicians relied on several non-invasive methods to gauge viability. Dobutamine stress echocardiography evaluates contractile reserve: if a dysfunctional segment shows improved wall motion during low-dose dobutamine infusion, that segment is considered viable. This test is inexpensive and widely available, but it depends heavily on operator skill and acoustic windows, and it provides limited information about the transmural extent of scar. Single-photon emission computed tomography (SPECT) using thallium-201 or technetium-99m sestamibi assesses perfusion and cell membrane integrity. Viable myocytes retain the tracer, while scar tissue shows a persistent defect. SPECT has moderate spatial resolution and can over- or underestimate viability, especially in the subendocardium. Positron emission tomography (PET) with FDG is considered a gold standard for viability, as it measures glucose metabolism. Mismatched segments (reduced perfusion but preserved metabolism) indicate hibernating myocardium. However, PET is expensive, less available, and involves radiation exposure. These techniques each have limitations in resolution, specificity, or risk, paving the way for magnetic resonance-based methods that offer superior soft-tissue contrast and no ionizing radiation.

Why Cardiac MRI Excels for Viability

Cardiac MRI provides a unique combination of high spatial resolution (typically 1–2 mm in-plane), excellent soft-tissue contrast, and the ability to characterize tissue using multiple contrast mechanisms. It can simultaneously assess anatomy, function, perfusion, and viability in a single comprehensive examination. The key advantage is the ability to directly visualize scar tissue and quantify its transmural extent with late gadolinium enhancement (LGE). Additionally, parametric mapping techniques (T1, T2, and extracellular volume fraction) offer quantitative insights into edema, fibrosis, and cellular health. These capabilities allow CMR to outperform older modalities in accuracy and reproducibility for viability detection.

Late Gadolinium Enhancement: The Cornerstone of Viability Imaging

LGE is the most widely used CMR technique for detecting myocardial scar. After intravenous injection of a gadolinium-based contrast agent, the dye distributes into the extracellular space. In normal, viable myocardium, the contrast agent is rapidly washed out. In scarred or fibrotic tissue, the extracellular space is expanded and the contrast agent accumulates, creating bright signal on T1-weighted images acquired 10–20 minutes after injection. The key insight is that the pattern and extent of enhancement correlate closely with viability. If LGE involves less than 50% of the transmural thickness, the segment is likely to recover function after revascularization. If more than 75% of the wall thickness is enhanced, recovery is very unlikely. This transmural threshold has been validated in multiple studies and is now a central part of clinical guidelines. Notably, no gadolinium-based contrast agent is retained in viable, non-fibrotic tissue, so a lack of enhancement indicates intact myocytes. LGE thus provides a binary readout (viable vs. non-viable) that is both sensitive and specific.

T1 and T2 Mapping: Quantitative Tissue Characterization

While LGE offers excellent detection of focal scar, it is less effective for diffuse myocardial fibrosis or edema that does not produce distinct bright segments. T1 and T2 mapping address this limitation. Native T1 mapping (without contrast) measures the longitudinal relaxation time of myocardium. Elevated native T1 values are seen in edema, fibrosis, and amyloidosis, while reduced T1 may indicate iron overload. After contrast, post-contrast T1 mapping can be used to calculate the extracellular volume fraction (ECV), which reflects the fraction of tissue occupied by extracellular space. In viability assessment, increased ECV indicates expanded interstitium from fibrosis or scar. T2 mapping is sensitive to myocardial water content; elevated T2 suggests edema, which can be a marker of acute ischemia or inflammation. For viability, the combination of elevated T2 (edema) without LGE suggests stunned or acutely injured but potentially viable myocardium—information that is valuable in acute coronary syndromes. These mapping techniques allow quantification of diffuse injury, which may be present in patients with non-ischemic cardiomyopathy or in the border zones of infarcts.

Stress Perfusion Imaging

First-pass perfusion imaging during pharmacological stress (usually with adenosine or regadenoson) evaluates the microvascular bed. In viability assessment, stress perfusion can identify segments with reduced blood flow that are still viable—so-called “ischemic but viable” myocardium. Such segments may be hibernating or stunned. When compared to LGE, a perfusion defect that is significantly larger than the scar suggests areas of inducible ischemia that could benefit from revascularization. Stress perfusion CMR has high diagnostic accuracy for detecting significant coronary artery disease and helps to risk-stratify patients. The combination of static and stress perfusion with LGE provides a complete picture of the balance between scar, ischemic burdens, and residual viability.

Advanced Sequences and Accelerated Imaging

Recent technological advances have made CMR faster and more robust. Three-dimensional (3D) LGE sequences acquire isotropic voxels that can be reformatted in any plane, allowing complete coverage of the left ventricle in a single breath-hold. This reduces scan time and improves detection of patchy or subendocardial scar. Motion correction and compressed sensing techniques allow high-quality imaging even in arrhythmic patients or those unable to hold their breath. Dark-blood LGE sequences suppress the blood pool signal, improving conspicuity of subendocardial scar. Diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI) are emerging as tools to assess myofiber architecture and integrity, potentially differentiating viable from non-viable tissue based on water diffusivity. These advanced sequences are increasingly being integrated into clinical protocols, expanding the armamentarium for viability assessment.

Clinical Implications of Accurate Viability Detection

The primary clinical use of viability imaging is to guide revascularization decisions in patients with ischemic cardiomyopathy. In the landmark STICH trial, the hypothesis that viability assessment would improve outcomes was not robustly confirmed in a randomized analysis, but subgroup and meta-analyses have consistently shown that patients with substantial viability (especially >50% of dysfunctional segments viable) have better survival and functional recovery after revascularization compared to those with minimal viability. Current ACC/AHA guidelines recommend viability assessment before revascularization in appropriately selected patients (JACC 2021 guideline). Moreover, the use of CMR-specific viability markers like transmural LGE extent helps avoid revascularization of fully scarred segments, reducing procedural complications and cost. Beyond revascularization, viability assessment also influences decisions about implantable cardioverter-defibrillator placement, as scar burden is a strong predictor of arrhythmic risk.

Clinicians must also consider that viability is not an all-or-none phenomenon. The presence of hibernating myocardium with preserved viability but reduced function may require a longer time to show recovery after revascularization—sometimes up to 6–12 months. Serial CMR can document functional improvement by measuring changes in wall thickening and ejection fraction. Additionally, in patients with acute myocardial infarction, CMR can distinguish between microvascular obstruction (which portends poor recovery) and areas of edema with intact myocytes (which generally recover). This information helps tailor early medical therapy and predicts adverse remodeling.

Future Directions in Cardiac MRI for Viability

Ongoing innovation seeks to push CMR beyond its current capabilities. Artificial intelligence (AI) is being applied to many aspects of CMR, from automated segmentation of LGE images to prediction of functional recovery based on imaging features. Deep learning models can analyze both LGE extent and texture to classify viability with high accuracy. AI also enables real-time motion correction and faster image reconstruction, making scans more comfortable and robust. Another major development is the emergence of non-contrast methods for viability imaging. Techniques such as native T1 mapping, T2 mapping, and diffusion-weighted imaging may reduce reliance on gadolinium—important for patients with severe renal impairment at risk of nephrogenic systemic fibrosis. Sodium-23 MRI and hyperpolarized carbon-13 MRI are experimental approaches that directly interrogate cellular metabolism and ion homeostasis, potentially offering new biomarkers of viability. For instance, elevated intracellular sodium levels indicate cell membrane damage, while lactate production maps via hyperpolarized pyruvate can identify metabolically active tissue. These methods are early-stage but hold promise for a more comprehensive metabolic assessment of viability.

Integration with other imaging modalities is another frontier. Hybrid PET/MRI systems combine the molecular sensitivity of PET (e.g., FDG uptake) with the high-resolution anatomy and tissue characterization of MRI. Such systems allow simultaneous acquisition of metabolism and scar, reducing scan time and providing perfectly registered images. Early studies show that PET/MRI can improve the specificity of viability assessment compared to either modality alone. Finally, 4D flow MRI can assess ventricular hemodynamics and vortice formation, which may indirectly reflect segmental function and viability. These advances are moving clinical practice toward a more quantitative, reproducible, and personalized approach to managing ischemic heart disease.

Conclusion

Cardiac MRI has evolved into the preeminent imaging modality for evaluating myocardial viability, offering detailed tissue characterization that is unmatched by older techniques. LGE remains the clinical standard, but mapping methods, stress perfusion, and advanced sequences provide complementary information that enhances diagnostic accuracy. Accurate viability assessment directly impacts therapeutic decisions, helping to identify patients who will benefit from revascularization and avoid unnecessary procedures in those with irreversible scar. With ongoing innovations in AI, non-contrast imaging, and hybrid systems, the role of CMR in viability assessment will continue to expand, promising even greater precision in the management of coronary artery disease and ischemic cardiomyopathy.

This article has been produced for informational purposes and should not replace professional medical advice or clinical judgment. For further reading, consult the 2021 AHA/ACC Guideline for Coronary Artery Revascularization and the RSNA review on CMR viability imaging.